Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

NCT03314935 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03314935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
November 21, 2017
Completion date
November 28, 2022
Enrollment
149 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc), colorectal cancer (crc), endometrial cancer, gastroesophageal cancer (gc), ovarian cancer, solid tumors